The city of Boston, Massachusetts, currently has 482 active clinical trials seeking participants for Cancer research studies.
The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT02000089
Recruiting
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Dana Farber Cancer Center, Harvard University, Boston, Massachusetts
Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Register for Updates
Cryoablation+Ipilimumab+Nivolumab in Melanoma
NCT05779423
Recruiting
The aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is resistant, or is growing, after receiving immunotherapy with a PD-1 inhibitor. The names of the study interventions involved in this study are: Cryoablation (an interventional radiology procedure that freezes part of a tumor) Ipilimumab (an immunotherapy) Nivolumab (an imm... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Metastatic Melanoma, Skin Cancer
Register for Updates
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
NCT06146920
Recruiting
The goal of this prospective study to investigate the use of circulating tumor DNA (ctDNA) to guide end of therapy decisions in patients with melanoma or non-small-cell lung cancer. The main question it aims to answer is: • Do patients with metastatic melanoma or non-small-cell lung cancer, who have received at least 12 months of immune checkpoint inhibition (monotherapy or in combination) with evidence of disease response/control on imaging and have no evidence of circulating tumor DNA, have... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Melanoma, Non-small Cell Lung Cancer
Register for Updates
Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
NCT05524428
Recruiting
The investigators will use a mixed methods study i.e. focus groups involving CHC staff as well as quantitative study which involves analyzing data that is available from the EHR and DRVS population management platform.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Codman Square Health Center, Boston, Massachusetts
Conditions: Colo-rectal Cancer
Register for Updates
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
NCT04305145
Recruiting
The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin cancer. The main questions this study aims to answer are: How many patients treated with infliximab experience steroid-free disease resolution after 7 weeks? How many patients treated with steroids experience steroid-free disease resolution after 7 weeks?
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event
Register for Updates
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
NCT04430699
Recruiting
This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: Cisplatin (standard of care drug) Pembrolizumab (investigational drug) Radiation Therapy (standard of care intervention)
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Vulvar Cancer, Vulvar Squamous Cell Carcinoma
Register for Updates
Multimodal Machine Learning Characterization of Solid Tumors
NCT04687969
Recruiting
This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness. This observational study involves [18F]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Adenocarcinoma of Prostate, Radical Prostatectomy, Hepatocellular Carcinoma (HCC), Glioma, Prostate Cancer, Renal Cell Carcinoma (RCC)
Register for Updates
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT02584244
Recruiting
The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
Register for Updates
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
NCT06176261
Recruiting
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Register for Updates
Dostarlimab and Cobolimab in Advanced Cervical Cancer
NCT06238635
Recruiting
This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +2 locations
Conditions: Cervical Cancer, Advanced Cervical Carcinoma, Metastatic Cervical Cancer, Metastatic Cervical Carcinoma, Recurrent Cervical Carcinoma
Register for Updates
Esophageal Cancer Multimodal Prehabilitation Study
NCT06027515
Recruiting
The goal of this research study is to investigate the feasibility of implementing a prehabilitation program that aims to improve a patient's physical, nutritional, and sleep health before surgery in an older, at-risk group with esophageal cancer.
Gender:
All
Ages:
65 years and above
Trial Updated:
03/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Esophageal Cancer, Esophageal Neoplasms
Register for Updates
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT04841148
Recruiting
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates